# Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies

> **NCT01224821** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 47 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab

## Key facts

- **NCT ID:** NCT01224821
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-12
- **Primary completion:** 1997-11
- **Final completion:** 2008-05
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224821, "Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01224821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*